To review available literature on the pharmacology, pharmacokinetics, dosing and administration, efficacy, and safety of the antiviral nucleoside analog telbivudine.
Data Sources:
Information was obtained from searching MEDLINE (1966–December 2005), International Pharmaceutical Abstracts (1970–December 2005), and the Cochrane Database of Systematic Reviews (4th quarter 2005) using the search words telbivudine, L-dT, L-deoxythymidine, L-nucleosides, and nucleosides. Abstracts from the Annual Meeting of the American Association for the Study of Liver Diseases and European Association for the Study of the Liver were also searched, including bibliographies from the identified articles.
Study Selection and Data Extraction:
Data from double-blind, placebo-controlled clinical trials and unpublished information were extracted.
Data Synthesis:
Telbivudine is a novel, orally administered nucleoside analog under development for use in the treatment of chronic hepatitis B. In contrast to other nucleoside analogs, telbivudine has not been associated with inhibition of mammalian DNA polymerase with mitochondrial toxicity. Telbivudine demonstrated potent activity against hepatitis B with significantly higher rate of response and superior viral suppression compared with lamivudine, the standard treatment. Telbivudine has been generally well tolerated, with low adverse effect profile, and at its effective dose, no dose-limiting toxicity has been observed.
Conclusions:
Telbivudine is a novel oral nucleoside analog effective in the treatment of chronic hepatitis B infection.
GanemDPrinceAM. Hepatitis B virus infection—natural history and clinical consequences. N Engl J Med2004;350:1118–29.
2.
LiawYFTaiDIChuCMChenTJ. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology1988;8:493–6.
3.
BeasleyRP. Hepatitis B virus: the major etiology of hepatocellular carcinoma. Cancer1988;61:1942–56.
4.
SchmilovitzHBen-AriZSikulerE. Lamivudine treatment for acute severe hepatitis B: a pilot study. Liver Int2004;24:547–51.
5.
LeeWM. Hepatitis B virus infection. N Engl J Med1997;337:1733–45.
6.
WongDKCheungAMO'rourkeKNaylorCDDetskyASHeathcoteJ. Effect of alpha-interferon in patients with hepatitis Be antigen– positive chronic hepatitis B: a meta-analysis. Ann Intern Med1993;119:312–23.
7.
PerilloRPSchiffERDavisGL. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. N Engl J Med1990;323:295–301.
8.
JanssenHLvan ZonneveldMSenrurkH. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet2005;365:123–9.
9.
MarcellinPLauGKBoninoF. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med2004;351:1206–17.
10.
DienstagJLSchiffERWrightTL. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med1999;341:1256–63.
11.
LiawYFCheungNWChangTT. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology2000;119:172–80.
12.
HonkoopPde ManRANiestersHGZondervanPESchalmSW. Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy. Hepatology2000;32:635–9.
13.
MarcellinPChangTTLimSG. Adefovir dipivoxil for the treatment of hepatitis Be antigen-positive chronic hepatitis B. N Engl J Med2003;348:808–16.
14.
HadziyannisSJTassopoulosNCHeathcoteEJ. Adefovir dipivoxil for the treatment of hepatitis Be antigen-negative chronic hepatitis B. N Engl J Med2003;348:800–7.
15.
SeiferMHamatakeRKColonnoRJStandringDN. In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir. Antimicrob Agents Chemother1998;42:3200–8.
BryantMLBridgesEGPlacidiL. Antiviral β-L-nucleosides specific for hepatitis B virus infection. Antimicrob Agents Chemother2001;45:229–35.
18.
SemizarovDGArzumanovAADyatkinaNB. Stereoisomers of deoxynucleoside 5'-triphosphates as substrates for template-dependent and -independent DNA polymerase. J Biol Chem1997;272:9556–60.
19.
WhittingtonRBrogdenRN. Zalcitabine. A review of its pharmacology and clinical potential in acquired immunodeficiency syndrome (AIDS). Drugs1992;44:656–83.
20.
WildeIMLangtryHD. Zidovudine. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy. Drugs1993;46:515–78.
21.
BrinkmanKSmeitinkJARomijnJAReissP. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy–related lipodystrophy. Lancet1999;354:1112–5.
22.
ZhouXJLimSGLaiCLPowDMBrownNAMyersMW. Pharmacokinetics of beta-L-deoxythymidine (LdT) in healthy subjects and patients with chronic hepatitis B virus infection (abstract). Antiviral Res2001;Hep-Dart abstracts: 92.
23.
LaiCLLimSGBrownNA. A dose-finding study of once-daily oral telbivudine in HBeAg-positive patients with chronic hepatitis B virus infection. Hepatology2004;40:719–26. DOI 10.1002/hep.2037
24.
ZhouXJMyersMChaoGDubucGBrownNA. Clinical pharmacokinetics of telbivudine, a potent antiviral for hepatitis B, in subjects with impaired hepatic or renal function (abstract). J Hepatol2004;40(suppl 1):S134.
25.
GishRGLeungNWWrightTL. Dose range study of pharmacokinetics, safety, and preliminary antiviral activity of emtricitabine in adults with hepatitis B viras infection. Antimicrob Agents Chemother2002;46:1734–40.
26.
WoltersLMHansenBENiestersHGZeuzemSSchalmSWde ManRA. Viral dynamics in chronic hepatitis B patients during lamivudine therapy. Liver2002;22:121–6.
27.
NowakMABonhoefferSHillAMBoehmeRThomasHCMcDadeH. Viral dynamics in hepatitis B virus infection. Proc Natl Acad Sci U S A1996;93:4398–402.
28.
WangCCHolteSHuangML. Kinetics of hepatitis B viral load during 48 weeks of treatment with 600 mg vs 100 mg of lamivudine daily. J Viral Hepatitis2004;11:443–7.
29.
TsiangMRooneyJFTooleJJGibbsCS. Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy. Hepatology1999;29:1863–9.
30.
WoltersLMHansenBENiestersHGDe HertoghDde ManRA. Viral dynamics during and after entecavir therapy in patients with chronic hepatitis B. J Hepatol2002;37:137–44.
31.
HanSHLeungNYTeoEK. Results of a one-year international phase IIb trial of LdT, and LdT plus lamivudine, in patients with chronic hepatitis B (abstract). J Hepatol2004;40(suppl 1):S16.
32.
DelaneyWEYangHMillerMDGibbsCSXiongS. Combinations of adefovir with nucleoside analogs produce additive antiviral effects against hepatitis B virus in vitro. Antimicrob Agents Chemother2004;s48:3702–10.
33.
PoynardTLaiCLLeungNY. Improving antiviral therapy in chronic hepatitis B: maximal viral suppression at week 24 correlates with better clinical efficacy at one year (abstract). J Hepatol2004;40(suppl 1):S130.
34.
DelaneyWYangHMillerMGibbsCXiongS. Lamivudine-resistant HBV is cross-resistant to LdT and LcT in vitro. J Hepatol2002;36(suppl 1):89.
35.
ZhouXJLloydDMFielmanBAMaureenMWChaoC. Absence of pharmacokinetic drug–drug interaction between telbivudine and lamivudine or adefovir in healthy subjects (abstract). J Hepatol2005;40(suppl 2):S197–8.
